Trade Summary

4 days ago, Schoenberg Mark, serving as Chief Medical Officer at UroGen Pharma Ltd. (URGN), sold 10,000 shares at $35.01 per share, for a total transaction value of $350,100.00. Following this transaction, Schoenberg Mark now holds 129,763 shares of URGN.

This sale represents a 7.15% decrease in Schoenberg Mark's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 22, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 24, 2026 at 10:22 AM ET, 2 days after the trade was made.

UroGen Pharma Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.